This article is more than 5 years old. Information may no longer be current.

Nicox begins phase 2 blepharitis treatment trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox has initiated a phase 2 clinical trial of NCX 4251, an ophthalmic suspension of fluticasone propionate nanocrystals, for the treatment of acute exacerbations of blepharitis.

The multicenter, randomized, double-masked, placebo-controlled, dose-escalation, 14-day trial will evaluate the safety and tolerability of NCX 4251 compared with placebo and is expected to include approximately 30 patients, according to a press release.

The trial’s main objective is to determine the doses of NCX 4251 to advance to phase 2b trials.

“There is no product approved in the United States solely for the treatment of blepharitis. We believe that the combination of a potent corticosteroid in our novel nanocrystal suspension together with application directly to the site of inflammation, where the disease originates, could lead to an efficacious and better tolerated product for the treatment of blepharitis,” Tomas Navratil, PhD, Nicox executive vice president, head of development, said in the release.

Topline results of the trial are expected in the fourth quarter.